Drug Profile
Cadonilimab - Akeso Biopharma
Alternative Names: AK-104Latest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Akeso Biopharma
- Developer Akeso Biopharma; Chipscreen Biosciences; Sun Yat-Sen University; The Third Affiliated Hospital of Soochow University
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cervical cancer
- Preregistration Gastric cancer; Oesophageal cancer
- Phase III Liver cancer; Non-small cell lung cancer
- Phase II Nasopharyngeal cancer; Rectal cancer; Renal cell carcinoma; Solid tumours
- Phase I/II Malignant melanoma; Pancreatic cancer; Peripheral T-cell lymphoma; Small cell lung cancer
Most Recent Events
- 28 Feb 2024 Efficacy and adverse events data from a phase II trial in Cervical cancer released by Akeso Biopharma
- 23 Jan 2024 Efficacy and adverse events data from a phase II trial in Liver cancer released by Akeso
- 23 Jan 2024 Akeso plans a registrational clinical trial in liver cancer (Late stage diseases, Combination therapy)